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Abstract
Obesity and diabetes represent a significant and escalating worldwide health burden. These conditions are charac-
terized by abnormal nutrient homeostasis. One such perturbation is altered metabolism of the sulphur-containing
amino acid cysteine. Obesity is associated with elevated plasma cysteine, whereas diabetes is associated with
reduced cysteine levels. One mechanism by which cysteine may act is through its enzymatic breakdown to produce
hydrogen sulphide (H2S), a gasotransmitter that regulates glucose and lipid homeostasis. Here we review evidence
from both pharmacological studies and transgenic models suggesting that cysteine and hydrogen sulphide play
a role in the metabolic dysregulation underpinning obesity and diabetes. We then outline the growing evidence
that regulation of hydrogen sulphide levels through its catabolism can impact metabolic health. By integrating
hydrogen sulphide production and breakdown pathways, we re-assess current hypothetical models of cysteine and
hydrogen sulphide metabolism, offering new insight into their roles in the pathogenesis of obesity and diabetes.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Obesity and diabetes
Obesity and type 2 diabetes are a major global health
burdens that have dramatically increased in prevalence
in the last few decades. According to the World Health
Organization, worldwide obesity has more than doubled
since 1980 [1]. As of 2014 it was estimated that 600
million worldwide could be classed obese, almost 10%
of the global population [1]. Type 2 diabetes has become
similarly common, with a global prevalence of 9% in
those over 18 years of age [2]. The two conditions are
strongly associated [3], largely due to obesity being a
strong risk factor for the development of insulin resis-
tance – a key underlying mechanism in type 2 diabetes
[4]. This relationship is not absolute, and many indi-
viduals remain metabolically healthy in spite of having
high fat mass, while others may suffer diabetes despite
normal fat mass [5]. A cardinal feature of both obesity
and type 2 diabetes is atypical carbohydrate and lipid
metabolism. Nutritional excess eventually overloads the
expanding adipose tissue, leading to ectopic accumula-
tion of lipid in key metabolic tissues such as the liver,
muscle and insulin-producing pancreatic islets [6,7].
This produces a lipotoxic stress [8] that leads to inflam-
mation and insulin-resistance in the adipose tissue, liver
and muscle, with a consequent dysregulation of glucose
homeostasis that precipitates diabetes. Specifically,
adipose tissue free fatty acid release is increased (a
process normally suppressed by insulin after feeding)
and glucose metabolism is skewed towards lipogenesis
[9]. In the liver, insulin-resistance increases hepatic
production of glucose by gluconeogenesis and glyco-
gen breakdown (which is normally suppressed by
post-prandial insulin action), contributing to hypergly-
caemia. Of note, lipid synthesis and transport pathways
remain sensitive to insulin in the liver, driving lipoge-
nesis and altering lipoprotein profiles that ultimately
contribute to atherosclerosis [10]. Insulin resistance
in muscle leads to impaired glucose disposal and oxi-
dation, thus exacerbating hyperglycaemia. Increased
demand for insulin engendered by hyperglycaemia
eventually leads to pancreatic β cell exhaustion, insulin
deficiency and frank diabetes.
Links between cysteine and obesity and diabetes
An emerging factor associated with obesity is altered
levels of the sulphur-containing amino acid cysteine.
Plasma total cysteine correlates positively with obesity,
as defined by body mass index [11,12], and in particular
with fat mass [13]. This relationship appears to be spe-
cific to cysteine, rather than amino acids in general, as no
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other amino acid shares the same strength of association
with obesity [14]. Plasma levels of other amino acids that
associate with obesity, such as cystathionine and gluta-
mate, normalize following gastric bypass surgery [15];
by contrast, plasma cysteine levels remain high, support-
ing the hypothesis that elevated cysteine is not merely
the consequence of increased fat mass but may mecha-
nistically underlie fat gain. This concept is supported by
evidence that in some rodent models, increasing dietary
cysteine levels can result in increased adiposity [16].
Themechanism bywhich cysteine could cause increased
tissue fat accumulation remains unresolved; one possi-
bility is that cysteine directly regulates energy expendi-
ture and/or appetite. Conflicting with its proposed role
in fat mass gain, there is evidence that cysteine reduces
appetite in humans and in rodent models [17]. Alterna-
tively, it has been reported that dietary cystine reduces
metabolic rate in mice, consistent with increased energy
storage [18]. Understanding any mechanism of action of
cysteine with respect to wider metabolic control must
also take into account that, contrary to its relationship
with obesity, type 2 diabetes has, in some studies, been
associated with lower plasma cysteine levels [19].
Hydrogen sulphide as a metabolite of cysteine;
clinical correlates with obesity/diabetes
In addition to the potential effects of cysteine per se,
it is possible that metabolites of cysteine could be
crucial. In this regard, cysteine is a critical substrate
for the intracellular generation of hydrogen sulphide
(H2S), an enzymatically produced physiologically
active gasotransmitter. Hydrogen sulphide has emerged
as an important factor in the modulation of insulin
action in tissues such as liver, adipose tissue and islets
of Langerhans. In contrast to plasma total cysteine,
which has a positive correlation to obesity and adiposity
[14], plasma hydrogen sulphide has been found to
be negatively correlated with measures of adiposity,
in particular waist circumference and waist:hip ratio
[20]. In this study, hydrogen sulphide was lowest in
subjects with obesity and type 2 diabetes, although
regression analysis suggested that the adiposity was
the main driver for predicting low plasma hydrogen
sulphide. Lower plasma hydrogen sulphide levels were
confirmed independently in another cohort of type 2
diabetes subjects [21]. Thus, cysteine and hydrogen sul-
phide have opposing relationships in obesity but share
the same negative correlation with type 2 diabetes. It
should be noted that, as accurate hydrogen sulphide
measurements from plasma are technically challenging
[22], these findings remain preliminary.
Hydrogen sulphide: production, breakdown
and mechanisms of action
Hydrogen sulphide was first discovered to be an endoge-
nously produced, physiologically active compound in
rodent brain [23,24], and previously was regarded as a
lethal respiratory toxin. A significant route of hydrogen
sulphide production is the reverse transulphuration
system, whereby homocysteine is converted to cysteine
via cystathionine. The two steps of this metabolic con-
version are carried out by the predominantly cytosolic
enzymes cystathionine β-synthase (CBS) and cystathio-
nine γ-lyase (CSE; also referred to as CTH) [25,26].
Both CBS and CSE are capable of a number of related
but distinct enzymatic conversions, with hydrogen
sulphide formed as a product of some of these reac-
tions [27,28] (Figure 1). The relative contribution of
these two enzymes to hydrogen sulphide production
are dependent on tissue-specific enzyme levels, sub-
strate and co-factor availability, and activators such
as S-adenosyl methionine [27,28]. Mercaptopyruvate
sulphur transferase (MPST; also referred to as MST)
may also generate hydrogen sulphide through the
cysteine transamination product 3-mercaptopyruvate
[29]. MPST acquires the sulphur atom from mercap-
topyruvate to form a persulphide intermediate, which
is released as hydrogen sulphide in the presence of
thioredoxin or other reducing agents [30].
Significantly, hydrogen sulphide breakdown is often
overlooked, but has the potential to regulate physi-
ological levels and may be important in preventing
toxic accumulation in tissues. Clearance of hydrogen
sulphide can occur by at least two mechanisms; the most
characterized is oxidation by mitochondria through a
respiratory route (Figure 2). This pathway has estab-
lished hydrogen sulphide as the first non-carbon-based
respiratory fuel in mammalian systems [31]. The pro-
posed canonical breakdown pathway involves sulphide
quinone oxidoreductase (SQR; also referred to as
SQRDL), persulphide dioxygenase (also referred to
as Ethe1, or sulphite dioxygenase), and thiosulphate
sulphur transferase (TST; also referred to as rhodanese),
[32,33]. The main products of this oxidation appear
to be sulphite and thiosulphate. Sulphite itself can be
further oxidized to sulphate by mitochondria by the
action of sulphite oxidase (SOX; also referred to as
SUOX), in a mechanism that can contribute electrons to
the electron transport chain via cytochrome c [34,35]. A
less established route for hydrogen sulphide catabolism
may involve reaction with iron-heme species present,
for example, in red blood cells and the mitochondrial
cytochrome c oxidase [36,37]. In vitro, the products
of heme-mediated oxidation are polysulphides and
thiosulphate, rather than sulphite [38]. It is noteworthy
that sulphate, sulphite, thiosulphate and polysulphide
species all have significant bioactive properties, extend-
ing the potential physiological impact of cysteine
metabolism and hydrogen sulphide production to the
activities of these metabolites [39–42].
A number of distinct mechanisms of hydrogen sul-
phide action have been proposed for regulating cellular
function. One mechanism of action is regulation of the
anti-oxidant status of cells. The lowmicromolar concen-
trations of endogenous hydrogen sulphide, compared to
the millimolar concentrations of more established thiol
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 238: 321–332
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Figure 1. Transulphuration – a source of cysteine and sulphide. CBS and CSE link cysteine generation from homocysteine, an intermediate
of the methionine cycle, with sulphide generation. CBS and CSE can be regulated at substrate, protein and RNA levels, and thus dynamic
changes in the flux of both cysteine and sulphide production is predicted to be possible in tissues
antioxidants such as glutathione and cysteine (free and
protein-bound), suggest that hydrogen sulphide likely
plays an indirect role in the antioxidant capacity of cells
through its signalling functions [43]. In an early study
of this property, primary cortical neurons were protected
from glutamate-induced cell death by administration of
100 μM sodium hydrogen sulphide (NaHS), an inor-
ganic source of hydrogen sulphide [44]. In that study
hydrogen sulphide increased cystine import and glu-
tathione production. There is also emerging evidence
that hydrogen sulphide interacts with nitric oxide sig-
nalling [45,46]. Hydrogen sulphide reacts with nitric
oxide to form nitrosothiol, and in some circumstances
may stimulate cGMP signalling as may nitric oxide.
Endogenous production of nitrosothiol was also mea-
sured in that study, suggesting a physiological role for
direct sulphide–nitric oxide reactions. Modification of
proteins by sulphydration (or persulphidation) is a fur-
ther mechanism by which hydrogen sulphide may alter
protein function. Thismodification refers to the presence
of an additional sulphur atom attached to a thiol, such as
cysteine, essentially a persulphide group. Formation of
persulphides through hydrogen sulphide requires either
oxidation of the hydrogen sulphide prior to reaction with
a thiol, or reaction of hydrogen sulphide with an already
oxidized species, such as a disulphide group [47–49].
Sulphydrationmodification regulates the activity of ATP
sensitive potassium channels, other membrane ion chan-
nels, kinases and transcription factors [48,49] to elicit
diverse biological effects. A persulphide cysteine is a
known intermediate of the mercaptopyruvate sulphur-
transferase enzyme catalytic cycle [50], suggesting that
persulphide formation may increase reactivity of other
active site cysteines.
Hydrogen sulphide in the liver: enhancing glucose
production and lipid oxidation?
Investigation into whether, and how, sulphide influences
hepatic function is at an early stage. Existing data sup-
port the view that sulphide promotes glucose produc-
tion, enhances lipid oxidation and inhibits insulin action
[51,52].
In the study by Zhang et al [51], treatment of clonal
HepG2 hepatocyte cells with 10–100 μMNaHS reduced
glucose consumption and reduced glycogen levels in
association with reduced glucokinase activity. In con-
trast, phosphoenol pyruvate carboxykinase (PEPCK)
activity and gluconeogenesis rates were increased by
similar concentrations of NaHS in these cells. Notably,
NaHS blocked stimulation of glucose consumption
following insulin treatment, and this was associated
with a reduction in phosphorylation (activation) of the
insulin-signalling intermediate AKT. A feedback mech-
anism between hydrogen sulphide and insulin signalling
was uncovered, with insulin exposure reducing CSE
levels and hydrogen sulphide production. Reversal of
this regulatory loop was observed when the HepG2
cells were rendered insulin-resistant through chronic
culture in high glucose. In these cells, CSE protein was
increased, as was hydrogen sulphide production.
In vivo, Wu et al [52] reported that daily injec-
tions of 50 μmoles/kg NaHS administration during a
16 week high-fat diet regime prevented diet-induced
liver damage and increased markers of lipid oxida-
tion. Specifically, hepatic expression of fatty acid
synthase was reduced and expression of carnitine
palmitoyltransferase-1 was increased. High-fat diet-
induced oxidative damage, as assessed by measuring
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 238: 321–332
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Figure 2. A model for cysteine and sulphide metabolism: bold capitals, enzymes discussed in this review; red arrows, chemical transforma-
tions; a red O2 is indicated where oxygen is consumed; orange arrows, movement of sulphide to mitochondrial components; blue arrows,
equilibrium of cysteine with protein and glutathione pools; green, main urinary excreted end products of sulphur metabolism; thiosulphate
and polysulphide metabolism remain controversial and are indicated as such with question marks; not indicated is the fact that methionine
and cysteine can enter the system as part of protein-containing diets. It is hypothesized that the balance of dietary intake, and flux through
these pathways, influences the steady state of cysteine and sulphide and thereby contributes to metabolic control of the cell
hepatic malondialdehyde, was reduced in the NaHS-
injected mice, consistent with the findings of increased
superoxide dismutase and glutathione peroxidase
activity.
Taken together, hydrogen sulphide appears to oppose
insulin action in the liver, and may mechanistically
contribute to hepatic insulin resistance. Intriguingly,
by enhancing glucose production and lipid oxidation,
hydrogen sulphide mimics the actions of glucagon
and/or adrenaline. This property fits with the increased
production of hydrogen sulphide found in mice under
dietary restriction [53] and clinical findings that hydro-
gen sulphide levels are low in obesity and type 2 diabetes
[20,21]. This is consistent with the loss of potentially
beneficial lipid oxidation effects and dysregulated
hepatic lipid metabolism in these states. However,
from the mechanistic studies above, low hydrogen sul-
phide levels would predict improved insulin sensitivity
with respect to hepatic glucose homeostasis, which is
clearly not the case in human type 2 diabetes. A full
understanding of the potentially distinct regulation of
glucose and lipid homeostasis by hydrogen sulphide
signalling will be important to elucidate. A clearer
understanding of the relationship between enzyme
levels for hydrogen sulphide production, breakdown
and the consequent steady-state levels in liver and other
key metabolic tissues in diabetes and obesity is also of
critical importance.
Hydrogen sulphide in adipose tissue: enhancing
glucose disposal and increasing conditions
for lipid storage?
Early studies with primary rat adipocytes suggested that
hydrogen sulphide prepared as a saturated gas solution,
and used effectively at doses in the range 10–1000 μM,
could inhibit glucose uptake, thereby opposing insulin
action [55]. This finding has not been consistently repli-
cated [56,57], albeit some of the work in these later stud-
ies used NaHS, or sodium sulphide (Na2S) as a means
of introducing hydrogen sulphide to their systems.
Studies of differentiated 3T3-L1 adipocytes have
generally supported the pro-insulin and pro-fat storage
effects of hydrogen sulphide. High-glucose culture
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 238: 321–332
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conditions of differentiating 3 T3-L1s, associated with
insulin resistance, was found to reduce protein levels
of molecular markers of the insulin-signalling pathway,
including PI3Kinase and phospho-AKT as well as PIP3
levels [56]. These effects were reversed by 10–100
μM Na2S, 100–1000 μM cysteine or the addition of
insulin to the medium. The same authors also showed
that reducing the insulin receptor level using siRNA
blocked these effects of Na2S on signal transduction.
In another study, high-glucose medium conditions
were found to reduce CSE mRNA, coincident with
reduced production of the insulin sensitizer adiponectin
and increased production of the pro-inflammatory
factor MCP-1 [57]. The addition of 10–50 μM NaHS
or forced expression of CSE reversed these effects.
Finally, treatment with the compound GYY4137 (50
μM) or NaHS (50 μM) throughout the differentiation
of 3 T3-L1 cells led to the increased formation of lipid
droplets and inhibition of adrenergic receptor-stimulated
lipolysis [58]. Consistent with these findings, admin-
istration of GYY4137 at 200 μmoles/kg/day to mice
reduced lipolysis, although no change in adiposity was
observed [59]. GYY4137, formally (p-methoxyphenyl)
morpholino-phosphinodithioic acid, is claimed to
release hydrogen sulphide slowly, and is used in an
effort to mimic longer-0term, and potentially more
physiological, levels of the gas. However, the backbone
structure of a donor such as GYY4137 could contribute
to cellular effects, and how this is controlled for is not
clear in this and similar studies. There are concerns
over how to manipulate hydrogen sulphide levels in a
physiologically appropriate manner, and the emergence
of new donors will help future studies in this regard
[60].
Overall, a model whereby hydrogen sulphide pro-
motes insulin effects in the adipocyte could be proposed
through its anti-lipolytic action, although with respect
to glucose uptake and lipogenesis its role is less clear.
Hydrogen sulphide may also contribute to fat storage by
indirectly maintaining or supporting insulin sensitivity
in this tissue. Cysteine, when it has been studied in the
context of adipose function, largelymimics the effects of
hydrogen sulphide [54,55,58] and supports the hypoth-
esis that it is a pro-obesogenic factor. The notion that
hydrogen sulphide may mediate some of these effects is
perhaps not itself surprising; however, this does not eas-
ily fit with the initial findings that obesity is correlated
with low plasma levels of hydrogen sulphide.
Cysteine, hydrogen sulphide and insulin-secreting
pancreatic 𝛃 cells
Over the last decade, hydrogen sulphide and/or cysteine
have been shown to regulate insulin secretion from pan-
creatic islets, or clonal insulin-secreting cells such as
MIN6, INS-1E andHIT-T15. A consistent finding is that
either cysteine or hydrogen sulphide can inhibit insulin
release from β cells, particularly following stimulation
with glucose [61–66]. It has been proposed that cys-
teine may mediate its effects, in part, via production of
hydrogen sulphide, as CSE and CBS are expressed in the
whole pancreas [67]. Indeed CSE is specifically induced
in β cells by high glucose [65]. Hydrogen sulphide,
added as gas-saturated solution to 100 μM, enhances
K-ATP channel opening, whereas NaHS at 100 μM
inhibits L-type VDCC calcium channels, both mech-
anistically consistent with reduction of insulin release
[61,68]. Sulphydration of K-ATP channels has been
demonstrated [69] and may contribute to the effect of
hydrogen sulphide on insulin secretion. Regulation of
mitochondrial respiratory function per se by hydrogen
sulphide may be of further importance, given the key
role of the ADP:ATP ratio on the secretory function
of islet cells. Apart from a role in regulating insulin
secretion per se, hydrogen sulphide may regulate other
aspects of β cell physiology, including viability. In the
stretptozotocin-induced diabetes model, elevated hydro-
gen sulphide was implicated in contributing to β cell
failure [70] and hydrogen sulphide prepared as satu-
rated gas solution, administered at doses of 50–200
μM, were found to decrease the viability of INS-1E
cells in culture [71]. In contrast, NaHS used at 100 μM
was found to have a protective role in maintaining islet
function and viability following high-fat feeding in rats
[72]. Differences in the dose and duration of expo-
sure may be a factor determining the overall effect of
hydrogen sulphide on islet function, as in other tissues.
Regulation of endogenous hydrogen sulphide produc-
tion is also a complex process. Exposure to 20mM glu-
cose decreased hydrogen sulphide production in INS-1E
insulinoma cells [61], whereas similar glucose expo-
sure stimulated expression of CSE in primary mouse
islets [65]. Plasma levels of hydrogen sulphide in a vari-
ety of diabetic models also reveals a complex picture.
Lowered [73–75] and elevated [76,77] levels have been
reported in blood or plasma of type 1 and type 2 dia-
betes models. Even considering type 2 diabetes models
exclusively, the aetiology of the diabetic state is different
across the studies and the methodologies used to derive
blood or plasma measurements of hydrogen sulphide
are discordant, and thus interpretation remains some-
what controversial. If the current consensus, that hydro-
gen sulphide suppresses insulin secretion, holds, then
the low hydrogen sulphide levels found in the plasma of
type 2 diabetic patients [21,22] may be a compensatory
response. This may be permissive for the development
of hyperinsulinaemia, which is required to maintain nor-
mal glucose levels in an insulin-resistant state. It appears
a critical issue to clarify the effects of hydrogen sul-
phide on islet function, development and dysfunction in
diabetes.
Lessons from genetic models with altered cysteine
and sulphide metabolism
Complementing pharmacological and association stud-
ies, genetic models relevant to the production and
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 238: 321–332
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metabolism of cysteine have been informative. So far,
there has been a tendency to find that in those mod-
els resulting in lowered plasma total cysteine levels,
lower adiposity is also observed whereas lean mass is
largely unchanged [78]. Notably, few of these mod-
els have been studied with respect to their hydrogen
sulphide levels. The models summarized below pro-
vide insight into the regulation of, and phenotypic
consequences of, cysteine and hydrogen sulphide
perturbation.
The transulphuration pathway: CBS and CSE
Insights into the metabolism and physiology of cysteine
have been obtained from the study of transgenic manip-
ulation of the genes Cbs and Cse. Mice homozygous
for a knockout of the Cbs gene (Cbs−/−) rarely sur-
vive after age 5 weeks [79]. For this reason, most stud-
ies report on Cbs deficiency, rather than full knockout
of the gene. By studying heterozygotes [80] or Cbs−/−
that transgenically express a hypermorphic human CBS
enzyme [81], Cbs−/− have been studied but, by neces-
sity, experiments are restricted to very young mice [82].
Cse gene knockout (Cse−/−) is not associated with gross
abnormality or lethality unless cysteine is limited in
the diet [82,83]. Genetic backgrounds can significantly
influence the phenotypic observations made with these
geneticmodels. Lethality before adulthood of theCbs−/−
is observed on a C57BL/6 J, DBA/2 J or BALB/cA back-
ground, whereas on a C3H/HeJ background significant
numbers of pups survive [84]. Indeed, Cbs−/− mice that
survive on the C3H/HeJ genetic background lose many
of the phenotypic aspects considered typical for this
model, suggesting induction of a compensatory system.
In spite of these caveats, some consistent findings
relating to cysteine metabolism are summarized here.
Knockout or deficiency of either Cbs or Cse in mice
alters cysteine metabolism, consistent with their role in
cysteine production from methionine. In some studies,
this is reflected by lowered plasma or tissue levels of cys-
teine in Cbs [85a] and Cse-knockout or -deficient mice
[83,86]. Hyperhomocysteinaemia is another consistent
finding in these genetic models [80,82,87]. Notably,
homocysteine is a long-established risk factor for vas-
cular disease when elevated [88]. Another prediction of
lowered cysteine production in tissue is reduced tau-
rine. Cysteine dioxygenase (CDO) activity in liver, a first
step in taurine synthesis, is increased when cysteine is
elevated [89]. Consistent with this, Cse−/− and Cbs−/−
mice have low plasma taurine compared to control mice
[82]. Also consistent with a deficiency in cysteine, glu-
tathione levels are lower in the liver of Cbs−/− [85] and
Cse−/− [83] mice. Moreover, in the Cse−/− model, glu-
tathione levels were normalized when cysteine was sup-
plemented in the diet [83].
An expectation from Cbs- and Cse-deficient models
is reduced hydrogen sulphide synthesis. In some studies
this is the case. Lower plasma hydrogen sulphide levels
have been reported in Cse−/− [83,86,87] and Cbs het-
erozygotemousemodels [80]. The expected reduction in
hydrogen sulphide levels is not always observed in these
models, for example liver hydrogen sulphide levels were
no different from controls in Cse−/− [87]. Furthermore,
in that study protein levels of MPST, capable of hydro-
gen sulphide production, were increased. Moreover, sul-
phide quinone oxidoreductase (SQR) levels, important
for oxidation of hydrogen sulphide, were elevated in
this Cse−/− model, not expected in a model of hydro-
gen sulphide insufficiency. These findings highlight that
a complex interplay and feedback mechanism(s) exists
to regulate hydrogen sulphide signalling and the resul-
tant phenotypic consequences.
Of relevance to adiposity, in one study of Cbs−/−
hypomorphic mice, weight gain and in particular fat
mass were lower than controls [90]. When maintained
on a high-cysteine diet, Cse−/− mice are typically of
normal body weight. On a cysteine-restricted diet, how-
ever, weight loss is apparent [82,83], including reduced
fat mass [83]. Supplementing drinking water with cys-
teine (1mg/ml) partly reversed this weight loss, whereas
daily intraperitoneal injection of NaHS (39 μg/kg), did
not [83]. A more recent study of Cse−/− mice on an
atherogenic diet also found reduced weight gain com-
pared to controls [91].
Little is known about glycaemic control in theCbs and
Cse knockout models. Very young (2week-old) Cbs−/−
mice have lower plasma glucose levels, whereas com-
parably young Cse−/− mice do not [92], a finding that
may simply reflect the severity of the Cbs−/− phenotype
and makes assessment of the direct effects of hydro-
gen sulphide on glucose homeostasis difficult. Hepatic
glycogen was higher in fed or mildly fastedCse−/− mice,
implying enhanced glucose storage in this tissue [51].
Indeed, primary hepatocytes from these Cse−/− mice
exhibited increased glucose uptake and reduced glu-
coneogenesis when compared to control hepatocytes.
Moreover, islets fromCse−/− mice secreted more insulin
in response to glucose [68]. In contrast to thesemetaboli-
cally favourable phenotypes, another group reported that
Cse−/− mice fed a high-fat diet developed more severe
glucose intolerance after 6 months [72]. Given the com-
plexity of changes attributable to lack of CSE enzyme
activity, it remains unclear whether a change in hydro-
gen sulphide production is a primary mediator of altered
glucose homeostasis.
More established, perhaps, are the profound effects
on lipid metabolism and inflammatory pathology found
in the liver of Cbs and Cse genetic models. Livers of
Cbs−/− hypomorphic mice develop hepatic fibrosis and
steatosis [79,93]. In another study, Cbs−/− hypomorphic
mice showed increased hepatic mRNA levels for genes
encoding lipid synthesis enzymes, and genes involved
in the endoplasmic stress response [94]. Cbs−/− hypo-
morphic and Cbs−/− mice are reported to have lower
plasma levels of HDL and higher LDL, non-esterified
fatty acids and triglycerides [82,95]. A reduction in
β-oxidation of fatty acids is part of the mechanism for
these phenotypes [95]. By contrast, Cse−/− mice are
protected from oxidative damage in the liver following
lipopolysaccharide and galactosamine challenge [87].
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Cse−/− mice in some models appear normal with respect
to lipid phenotypes [82]. However, Cse−/− mice exposed
to an atherogenic diet had higher total cholesterol levels,
lower plasma triglycerides [91] and developed more
extensive atherosclerotic lesions in their vessels. These
phenotypes were reversed, in part, by intraperitoneal
injection of NaHS (39 μg/kg), supporting that attenu-
ated production of hydrogen sulphide in Cse−/− mice
is an important factor in disease development. Of note,
the correction of lipid abnormalities in this study did
not prevent development of lesions in Cse−/− mice,
further implicating vessel-specific hydrogen sulphide
signalling in atherosclerosis.
It is clear that CBS and CSE have roles relevant to
glucose and lipid metabolism in the liver, and perhaps
throughout the body, and have the potential to influ-
ence adiposity and diabetes. The relationship of reduced
adiposity found in the gene deficiency models fits the
clinical relationship with plasma cysteine, but less so
with that reported for plasma hydrogen sulphide. Further
work is required to clarify these important relationships.
Reductive sulphide production: MPST
Another established source of endogenous sulphide is
from the reductive removal of persulphide at the active
site of 3-mercaptopyruvate sulphur transferase (MPST)
[96]. 3-Mercaptopyruvate (3-MP) is a product of the
transamination of cysteine. MPST then acquires the
sulphur from 3-MP as a persulphide into its active site,
which, in combination with reduced thioredoxin, can be
released as hydrogen sulphide. A Mpst−/− mouse has
been generated, but no reports exist from this model
describing cysteine, sulphide or phenotypes relating to
adiposity, carbohydrate or lipid metabolism [97].
Methionine cycle: PEMT and BHMT
The methionine cycle, upstream of the transulphura-
tion pathway, uses methionine as a source of methyl
groups for various reactions. This includes synthesis
of phosphatidyl choline, which is catalysed by phos-
phatidylethanolamine N-methyl transferase (PEMT).
Subsequent to this, the cycle generates homocysteine,
from which cystathionine, and subsequently cysteine,
can be formed. Homocysteine can also be methy-
lated to regenerate methionine. One enzyme capable
of this methylation is betaine homocysteine methyl-
transferase (BHMT). Knockout mice for both Pemt
and Bhmt have been generated. Pemt−/− mice show a
protected metabolic phenotype, resisting the weight
gain and deterioration of glucose metabolism caused
by a high-fat diet [98,99]. Apart from having lower
homocysteine levels in plasma [100], no data exist
regarding tissue or plasma cysteine in Pemt−/− mice.
The Bhmt−/− mouse exhibits lower plasma cysteine,
reduced fat mass, smaller adipocytes and improved
glucose disposal following insulin injection [101]. The
involvement of hydrogen sulphide in these phenotypes
remains to be investigated. However, methionine cycle
intermediates are known to activate CBS activity [102],
consistent with a potential impact of the methionine
cycle on sulphide generation and its effects.
Glutathione turnover: GGT and GCLM
Glutathione offers a major source of cysteine in the cell,
with steady-state concentrations generally far greater
than that of cysteine. The production of glutathione from
cysteine is contributed to by glutamate–cysteine ligase
(GCL). A subunit of this complex (GCLM) has been
knocked out in mice and results, as expected, in lower
plasma and tissue glutathione but also in greatly reduced
plasma cysteine [103]. Strikingly, these Gclm−/− mice
appear significantly affected in their adipose and liver
metabolism; displaying a higher metabolic rate despite
impaired whole-body lipid oxidation, reduced fat stor-
age in adipose, reduced fat accumulation in liver, greater
oxidative stress, yet maintained insulin sensitivity on a
high fat diet. Another study of this model found lower
mRNA levels for genes involved in fatty acid oxidation
and synthesis, as well as a profound protection from the
development of hepatic steatosis [104].
Another enzyme relevant to glutathione turnover is
γ-glutamyl transferase (GGT), which is involved in
recycling glutathione to cysteine. The enzyme partic-
ipates in a number of other reactions and cannot be
considered uniquely related to cysteine metabolism.
Ggt−/− mice display alterations in glutathione and lower
cysteine in plasma, suggesting that recycling of cysteine
from glutathione represents an important source of
the amino acid in tissues. Fat mass changes were not
reported, but the mice were significantly reduced in
body weight [105].
Taurine biosynthesis: CDO and CSAD
Taurine is an essential and abundant metabolite of cys-
teine. The first step in its synthesis is by oxidation of
a cysteine with molecular oxygen by the enzyme cys-
teine dioxygenase. The phenotype of mice with knock-
out of the cysteine dioxygenase gene (CDO) does not
follow the predictions relating to cysteine levels and adi-
posity. Thus, while Cdo−/− mice have elevated cysteine
levels, as expected, the mice exhibit lowered fat mass
[106]. However, hydrogen sulphide levels are elevated
in Cdo−/− mice, which does fit the reported clinical rela-
tionship between hydrogen sulphide and obesity. The
phenotype of Cdo−/− mice may be due to the toxicity of
hydrogen sulphide and other altered metabolites, rather
than a metabolic influence on fat mass per se [107].
Cysteine sulphinic acid decarboxylase (CSAD) follows
on from CDO in the taurine biosynthesis pathway,
converting cysteine sulphinate to hypotaurine. CSAD
may prevent accumulation of sulphite – a spontaneous
breakdown product of cysteine sulphinate. A knockout
mouse has been generated [108] but the result is lethal
unless neonates are supplemented with taurine, and
few data exist regarding any effects on metabolism in
general.
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Genetic modification of the sulphide oxidation
unit (SOU) represents a target for manipulating
sulphide levels
While the genetic models discussed above largely
concern cysteine metabolism or cytoplasmic sulphide
generation, mitochondria are known to oxidize hydro-
gen sulphide, in part contributing to respiration, but
also to prevent toxic build-up. The known compo-
nents of this system have been referred to as the
sulphide-oxidizing unit (SOU). The SOU consists of
the sulphide quinone reductase (SQRDL), sulphur
dioxygenase (SDO/ETHE1) and thiosulphate sulphur
transferase (TST/rhodanese) [32,33]. In addition, sul-
phite is oxidized further to sulphate through sulphite
oxidase (SUOX) [34]. Together, this system is capable
of oxidizing sulphide into sulphate and thiosulphate
[109]. As the system is predicted to lower hydrogen
sulphide levels by oxidation via respiration, it is not
surprising that the Ethe1−/− mouse, a model of ethyl-
malonic encephalopathy, is characterized by hydrogen
sulphide levels in liver and muscle> 10-fold higher than
in control mice, and by a short life span [110]. As yet,
no reports exist for genetic manipulation of either the
SQRDL or SUOX genes, although they have been stud-
ied in other ways and are suggested to be essential for
the detoxification of sulphide and sulphite, respectively
[111,112]. New studies on mice with gene deficiency
of Tst are emerging, with phenotypes in the context
of ischaemia–reperfusion injury in the heart (outlined
in Abstract form [113]). A full analysis of phenotypes
related to metabolic disease are currently ongoing in our
laboratory and will add to the increasingly recognized
role for enzymes in the hydrogen sulphide breakdown
pathway in many physiological processes.
Summary of findings in genetic models of altered
sulphur metabolism with respect to obesity
Genetic and biochemical investigations have delin-
eated many of the important enzymes involved in
the metabolism of cysteine and hydrogen sulphide
(Figure 2). In the context of obesity, a number of the
gene knockout models presented above mirror the
clinical findings that obesity is associated with high
plasma total cysteine. Gene knockout of enzymes of
the methionine cycle (in particular Bhmt), the tran-
sulphuration pathway (Cbs and Cse) and glutathione
metabolism (Gclm and Ggt) all reduce body weight,
usually along with reduced adiposity, and present with
lowered plasma cysteine. As yet, no genetic model
has been described linking elevated cysteine to higher
adiposity. Indeed, the Cdo knockout mouse has been
shown to have significantly higher plasma cysteine and
yet reduced body weight.
The clinical finding that plasma hydrogen sulphide
correlates negatively with obesity is less well supported
by the evidence from transgenic models. Of the mod-
els discussed, the Cbs, Cse, Cdo and Sdo genetic mod-
els have, in some studies at least, reported changes in
plasma or tissue hydrogen sulphide, in the direction
that would be predicted by their biochemical functions.
However, in models where lower plasma hydrogen sul-
phide are found, such as the Cse- and Cbs-deficient or
-knockout mice, lower rather than higher fat mass has
been observed. The Cdo- and Sdo-knockout mice, on
the face of it, support the clinical relationship, as they
have elevations in hydrogen sulphide and lower body
weight. These elevations in hydrogen sulphide are, how-
ever, reported in tissue, not plasma, and little has been
reported about fat mass per se. Regardless of the similar-
ity or otherwise to the clinical findings, caution must be
exercised in translating adipose and whole body weight
phenotypes of genetic models. Phenotypes that result
from toxicity, as has been suggested for both the Sdo and
Cdo knockout, and some Cbs and Cse models, greatly
hamper interpretation.
The majority of models discussed above have a major
impact on sulphur amino acid metabolism, including
of cysteine and homocysteine. Genetic manipulation of
components of the SOU may allow assessment of the
contribution of hydrogen sulphide, and potentially sul-
phite, thiosulphate and sulphate, to lipid and carbohy-
drate metabolism, without necessarily interfering with
cysteine metabolism directly.
Summary of findings in genetic models of altered
sulphur metabolism with respect to diabetes
Some of the above findings, in agreement with the
existing clinical data, suggest that lowered cysteine
is associated with impaired glucose homeostasis or
insulin resistance. Few of the studies of the gene knock-
out models discussed above test this concept directly.
Perhaps significantly, Bhmt−/− mice show lower cys-
teine levels and reduced adiposity, but improved glu-
cose tolerance and insulin sensitivity. This association
between lower plasma cysteine does not support the
clinical data. Knockout of the transulphuration enzymes
CSE and CBS present with pathology in the liver
that might be considered diabetogenic; however, strict
assessment of glucose homeostasis and insulin sensi-
tivity is still lacking. Similarly, GCLM knockout mice,
while presenting with lower cysteine, glutathione and
increased oxidative stress, are reported to be compara-
ble to controls regarding insulin sensitivity. With respect
to hydrogen sulphide level, as data are lacking from the
some of the above models, little can be said regard-
ing its role in the observed phenotypes relating to dia-
betes or insulin function. In those knockout models
where hydrogen sulphide levels are reported (Cbs, Cse,
Cdo and Ethe1), a full investigation of potential dia-
betic phenotypes has not been reported. There therefore
remains considerable uncertainty regarding the genetics
of cysteine/sulphide-metabolizing enzymes with respect
to insulin resistance or diabetes.
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Conclusions and future directions
The association between obesity and cysteine in humans
appears robust. However, it remains possible that the
true mechanism underlying the association is a factor(s)
other than cysteine, which concurrently drives eleva-
tions in plasma cysteine. Data on the dietary effects of
cysteine and fat gain across a wide range of models
is lacking. Differences between rodent strains, dietary
sources and manipulation, the impact on microbiota
and interactions with the non-sulphur components of
the diet may all influence how dietary cysteine effects
adiposity. Similar issues apply to hydrogen sulphide’s
effects, which are obscured by a lack of standardiza-
tion in measurement and administration methods. The
field would benefit from a systematic analysis of tis-
sue and blood/plasma sulphur metabolites across the
key transgenic models. Robust methods for the measure-
ment of hydrogen sulphide will be required in order to
reflect true endogenous levels. The existence in blood
or tissue samples of polysulphides [83], acid-labile sul-
phur pools [114] and possible chemical interference by
other factors can confound measurement techniques and
result in wide variation in estimates of hydrogen sul-
phide [115]. Tissue-specific or inducible manipulation
may be particularly informative to minimize toxicity
and lethality that might result from whole-body gene
knockouts.
A full understanding of the impact of variation within
the homologous human genes of the cysteine–sulphur
metabolism pathway on metabolic parameters would
also be informative. Nevertheless, exogenous admin-
istration of cysteine or hydrogen sulphide inhibits
adrenergic-stimulated lipolysis from adipocytes
[14,59,60] and glucose-stimulated insulin release
from β cells [61–66]. Cysteine has further important
effects on glutathione and taurine production in the
liver, and thereby oxidative stress, lipid metabolism and
inflammation. Regulation of these hepatic processes by
hydrogen sulphide remains less clear, in large part due
to the aforementioned lack of standardized methodol-
ogy and variation in models and study designs. Direct
dose-sensitive effects of cysteine and sulphide on oxida-
tive stress, mitochondrial respiration and metabolic
rate in vivo will be important areas to resolve; the
stimulatory effects of sulphide on mitochondrial respi-
ration found with moderate, sub-toxic doses remains
an intriguing function of this gas, linked to protection
of the mitochondria from ischaemia–reperfusion injury
[116] and the ’cryoprotective-like’ properties first
ascribed to hydrogen sulphide [117]. Thus, although
considerable work is needed to understand exactly how
cysteine/sulphur metabolism relates to the develop-
ment and potential treatment of obesity and diabetes,
clear principles have been established, predominantly
through work explored in the field of inflammatory and
vascular biology, that these factors could be impor-
tant and novel therapeutic targets for cardiometabolic
diseases.
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